Carboplatin Injection
Brand names: Carboplatin, Kyxata
Category: Oncology
Unavailable 14Limited 9Available 4Not specified 4
FDA status: Current, To Be Discontinued · Last FDA update: Sep 22, 2026 · First posted: Feb 20, 2026 (in shortage 7 months) · 9 manufacturers, 31 listed presentations
As of Sep 22, 2026, the FDA lists Carboplatin Injection as being discontinued. Of 31 manufacturer presentations, 14 Unavailable, 9 Limited, 4 Available, 4 Not specified.
Ask your pharmacist: which of the 9 manufacturers below can they order right now, and whether a different strength or form of Carboplatin Injection is available. For alternatives, talk to your prescriber — see what to do if your medication is in shortage.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34) NDC 16729-295-34 |
Accord Healthcare Inc. | Unavailable | Estimated recovery: TBD |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12) NDC 16729-295-12 |
Accord Healthcare Inc. | Unavailable | Estimated recovery: TBD |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33) NDC 16729-295-33 |
Accord Healthcare Inc. | Unavailable | Estimated recovery: TBD |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31) NDC 16729-295-31 |
Accord Healthcare Inc. | Unavailable | Estimated recovery: TBD |
| Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60) NDC 63323-172-60 |
Fresenius Kabi USA, LLC | Unavailable | Next release November 2026. Check wholesalers for inventory. |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01) NDC 0703-4244-01 |
Teva Pharmaceuticals USA, Inc. | Unavailable | Estimated recovery: January 2027 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01) NDC 0703-4246-01 |
Teva Pharmaceuticals USA, Inc. | Limited | Estimated recovery: September 2027 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01) NDC 0703-4239-01 |
Teva Pharmaceuticals USA, Inc. | Limited | Estimated recovery: December 2028 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01) NDC 0703-4248-01 |
Teva Pharmaceuticals USA, Inc. | Limited | Estimated recovery: February 2027 |
| Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01) NDC 54288-164-01 |
Gland Pharma Limited | Unavailable | Discontinued; Distributed by BPI Labs, LLC |
| Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01) NDC 54288-165-01 |
Gland Pharma Limited | Available | Distributed by BPI Labs, LLC |
| Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01) NDC 55150-335-01 |
Eugia US LLC | Unavailable | On backorder. Recovery: late October 2026. Check wholesalers for inventory |
| Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45) NDC 50742-447-45 |
Ingenus Pharmaceuticals LLC | Not specified | Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01) NDC 54288-166-01 |
Gland Pharma Limited | Limited | Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC |
| Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01) NDC 55150-386-01 |
Eugia US LLC | Available | Check wholesalers for inventory |
| Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60) NDC 50742-448-60 |
Ingenus Pharmaceuticals LLC | Not specified | Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01) NDC 54288-167-01 |
Gland Pharma Limited | Limited | Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05) NDC 61703-150-05 |
Hospira, Inc., a Pfizer Company | Unavailable | Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22) NDC 61703-339-22 |
Hospira, Inc., a Pfizer Company | Limited | Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) NDC 60505-6282-3 |
Teyro Labs | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05) NDC 61703-262-05 |
Hospira, Inc., a Pfizer Company | Unavailable | Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50) NDC 61703-339-50 |
Hospira, Inc., a Pfizer Company | Limited | Limited Supply Available. Next Delivery and Estimated Recovery: December 2026 |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) NDC 60505-6282-6 |
Teyro Labs | Not specified | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18) NDC 61703-339-18 |
Hospira, Inc., a Pfizer Company | Limited | Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027 |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18) NDC 61703-360-18 |
Hospira, Inc., a Pfizer Company | Unavailable | Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) NDC 60505-6282-1 |
Teyro Labs | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56) NDC 61703-339-56 |
Hospira, Inc., a Pfizer Company | Limited | Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05) NDC 61703-600-05 |
Hospira, Inc., a Pfizer Company | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) NDC 60505-6282-7 |
Teyro Labs | Not specified | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug |
| Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50) NDC 83831-142-50 |
Avyxa Pharma, LLC | Available | - |
| Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08) NDC 83831-141-08 |
Avyxa Pharma, LLC | Available | - |
Related medications in shortage
Other Oncology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
No changes recorded yet.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Carboplatin Injection (FDA data as of Sep 22, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Carboplatin Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Check your inbox - click the confirmation link to activate
alerts for Carboplatin Injection.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/carboplatin-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).